BioSpace News Archive

Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”) a late-stage, pre-revenue diagnostics/medical device company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced the appointment of Mark W. Feinberg, M.D. as Chief Medical Advisor.

OWP Pharmaceuticals, Inc. is a privately held, neuroscience specialty pharmaceutical company, dedicated to developing and commercializing novel oral liquid formulations and supporting global philanthropy.

NiKang Therapeutics Inc. (“NiKang”),and AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company (“AVEO”) , today announced that they have entered into a clinical trial collaboration and supply agreement to evaluate NKT2152.

Hologic, Inc. announces the addition of the Aptima® SARS-CoV-2 assay to its Global Access Initiative, a program designed to expand access to critical diagnostic testing in resource-limited countries.

VBI Vaccines Inc. today announced that the first patient has been dosed in a second Phase 2a/2b clinical study evaluating VBI-2601 (BRII-179), an immunotherapeutic candidate targeting chronic hepatitis B virus (HBV).

Inscripta, Inc., The Digital Genome Engineering Company, today announced that it has appointed Kristala Prather , PhD, to serve on its Board of Directors.

Spruce Biosciences, Inc. today announced that Dr. Javier Szwarcberg, M.D., MPH, has been appointed Chief Executive Officer and as a member of the board of directors.

The Cystic Fibrosis Foundation announced today that it has invested in SalioGen Therapeutics to support the company’s preclinical research into a novel genetic therapy for cystic fibrosis.

Nucleix announced recent advances in its EpiCheck ® Next Generation Sequencing (NGS) platform and lung cancer detection program for early stage disease.

Equillium, Inc., a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, announced that Bruce Steel, Equillium’s chief executive officer, will present at the H.C. Wainwright Virtual BioConnect Conference.